JAK2-inhibitory

F. Cervantes, R. Mesa, C. Harrison

JAK inhibitors: beyond spleen and symptoms? 

Haematologica 2013; 98(2): 160-162

F. Cervantes, A. M. Vannucchi, J.-J. Kiladjian, H. K.Al-Ali, A. Sirulnik

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis 

Blood 2013; 122(25): 4047-4053

L. Červinek, M. Doubek

Ruxolitinib v léčbě primární myelofibrózy

Farmakoterapie 2013; 9(2): 120–123.

V. Gupta, P. Hari ,R. Hoffman

Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors

Blood 2012; 120(7): 1367-1379

C. Keohane, R. Mesa, C. Harrison

The Role of JAK1/2 Inhibitors in The Treatment of Chronic Myelofibrosis Neoplasms

American Society of Clinical Oncology 2013, 301-305

C. Harrison, J.-J. Kiladjian, H. Kathrin Al-Ali, H. Gisslinger, R. Waltzman, V. Stalbovskaya

JAK Inhibition Ruxolitinib versus Best Available Therapy for Myelofibrosis

The New England Journal of Medicine 2012; 366: 787-98.

J. Mascarenhas ,R. Hoffman

A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis

Blood 2013; 121(24): 4832-4837

R. A. Mesa, J. Gotlib, V. Gupta, J.V. Catalano, M.W. Deininger, A.L. Shields

Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial

Journal of Clinical Oncology 2013; 31: 1285-1292

R. A. Mesa, J.-J. Kiladjian, S. Verstovsek, H. K. Al-Ali, J. Gotlib, H.Gisslinger

Comparison of placebo and best available therapy for threatment of myelofibrosis in the phase 3 COMFORT studies 

Haematologica 2014; 99(2): 292-298

S. Verstovsek, F. Passamonti, A. Rambaldi, G. Barosi, P. J. Rosen, E. Rumi

A Phase 2 Study of Ruxolitinib, an Oral JAK1 and JAK2 Inhibitor, in Patiens With Advanced Polycythemia Vera Who Are Refractory or Intolerant to Hydroxyurea 

Cancer  2013

S. Verstovsek, R. A. Mesa, J. Gotlib, R.S. Levy, V.Gupta, J. F. DiPersio

A Double-Blind,Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

The New England Journal of Medicine 2012;366:799-807

S. Verstovsek, R. A. Mesa, J. Gotlib, R.S. Levy, V.Gupta, J. F. DiPersio

Efficacy,safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2 year follow up of COMFORT 1 

Haematologica 2013; 98(12): 1865-1871

S. Verstovsek, H. Kantarjian, R. A. Mesa, A. D. Pardanani, J. Cortes-Franco, D. A. Thomas

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis 

The New England Journal of Medicine 2010; 363: 1117-27

R. Wathes, S. Moule, D. Milojkovic

Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib 

The New England Journal of Medicine 2013; 369(2):1 97-198

B. S. Wilkins, D. Radia, C. Woodley, S. El Farhi, C. Keohane, C.N. Harrison

Resolution of bone marrow fibrosis in patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib

Haematologica 2013; 98: xxx